Rich Indians join the global party in vaccine company stocks
Synopsis
“The trend of diversifying assets and hedging strategies away from home markets took off in 2014-15 and accelerated during the course of the pandemic around March and April this year,” said Nitin Shakdher, a professional institutional investor and founder of Green Capital Single Family Office.
Mumbai: Rich Indians have joined the global investment game of buying stocks of pharma MNCs at the frontline of Covid vaccine development. In the last couple of months, especially in recent weeks, many high networth individuals and even a few retail investors have bought stocks of Moderna, Pfizer, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Abbott and Sanofi.It’s all perfectly aboveboard – the stock buys happen via the Liberalised
- FONT SIZEAbcSmallAbcMediumAbcLarge
ET
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Get Unlimited Access to The Economic Times
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
